Company news

Pacira Biosciences, Inc. (NASDAQ:PCRX) news

Pacira Biosciences, Inc. news releases on 6ix. Latest, Oct 5, 2026: Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL®…

Pacira Biosciences, Inc. (NASDAQ:PCRX) news

Press releases & updates

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

Pacira BioSciences Reports Second Quarter 2026 Financial Results

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America's Workforce

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026

Pacira BioSciences Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®

Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet

Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting

Egan-Jones Recommends Pacira Shareholders Support All Management Nominees

Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting

Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION

Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees

Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty

Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy

A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC

DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences

Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders

DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates

Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

Pacira BioSciences Mails Letter to Stockholders

Pacira BioSciences Reports First Quarter 2026 Financial Results

Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders

Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty

Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026

Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures

Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting

Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation

Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference

Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)

Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results

Pacira to Report 2025 Financial Results on Thursday February 26, 2026

Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices

Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences

DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.

Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical

DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance